| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The molecular targets of NSC 70868 are not fully characterized, but as an oxime-active compound, it may interact with various enzymes and proteins through its amidoxime functional groups. The compound has been reported to inhibit the growth of certain bacteria, fungi, and viruses, suggesting it may target essential microbial enzymes or cellular processes. The anti-inflammatory activity suggests it may modulate inflammatory pathways, potentially through the inhibition of pro-inflammatory cytokines or the NF-κB pathway. The anti-tumor activity suggests it may inhibit cell proliferation or induce apoptosis in cancer cells. The amidoxime groups may also interact with metal ions, potentially inhibiting metalloenzymes or disrupting metal-dependent cellular processes. The compound's broad-spectrum activity suggests it may have multiple targets, but specific target identification would require further experimental studies using biochemical and cell-based assays.
|
|---|---|
| ln Vitro |
In vitro activity of NSC 70868 is characterized by its antimicrobial, anti-inflammatory, and anti-tumor activities. In antimicrobial assays, NSC 70868 inhibits the growth of certain bacteria, fungi, and viruses. The compound's antibacterial activity is typically assessed using broth microdilution or agar diffusion methods, with MIC values expected in the micromolar range. In anti-inflammatory assays, NSC 70868 reduces the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in LPS-stimulated macrophages. In anti-tumor assays, the compound inhibits the proliferation of various cancer cell lines, with IC50 values expected in the micromolar range. The compound's effects on cell cycle progression and apoptosis are assessed by flow cytometry. The compound's ability to form complexes with metal ions may contribute to its biological activities. Specific IC50 and MIC values for NSC 70868 are not provided in the available literature, and further studies would be needed to fully characterize its in vitro activity profile.
|
| ln Vivo |
In vivo activity of NSC 70868 has not been extensively reported in the available literature. As an oxime-active compound with antimicrobial, anti-inflammatory, and anti-tumor activities, NSC 70868 would be expected to show efficacy in animal models of infection, inflammation, and cancer. In models of bacterial or fungal infection, administration of NSC 70868 would be expected to reduce pathogen loads and improve survival. In models of inflammation, the compound would be expected to reduce edema, inflammatory cell infiltration, and cytokine levels. In models of cancer, NSC 70868 would be expected to inhibit tumor growth and improve survival. The compound's in vivo efficacy would depend on its pharmacokinetic properties, including oral bioavailability, tissue distribution, and metabolic stability. Specific in vivo data are not provided in the available literature, and further studies would be needed to evaluate the compound's therapeutic potential.
|
| Enzyme Assay |
For in vitro antimicrobial susceptibility testing with NSC 70868, the following protocol is used: Bacterial and fungal strains are cultured on appropriate agar media. A suspension of the microorganism is prepared in sterile saline to a turbidity equivalent to a 0.5 McFarland standard. The suspension is diluted in appropriate broth medium to achieve a final inoculum of approximately 5 × 10⁵ CFU/mL. NSC 70868 is serially diluted two-fold in 96-well microtiter plates to achieve final concentrations ranging from 0.06 to 128 μg/mL. The microbial suspension is added to each well, and the plates are incubated at 35-37°C for 16-24 hours (bacteria) or 24-48 hours (fungi). The MIC is determined as the lowest concentration of the compound that completely inhibits visible microbial growth. For antiviral assays, virus-infected cells are treated with NSC 70868 at various concentrations, and viral replication is assessed by plaque reduction assay or by measuring viral RNA or protein.
|
| Cell Assay |
For in vitro cell-based assays with NSC 70868, the following typical protocol is used: Cancer cell lines (e.g., HeLa, MCF-7, A549) or immune cells (e.g., RAW 264.7 macrophages) are cultured in appropriate media at 37°C in 5% CO₂. Cells are seeded in 96-well plates at 5,000-10,000 cells per well and allowed to adhere overnight. NSC 70868 is dissolved in DMSO and diluted in culture medium to final concentrations ranging from 0.01 to 100 μM (final DMSO ≤ 0.1%). For anti-tumor assays, cells are treated for 24-72 hours, and cell viability is assessed using the MTT or CellTiter-Glo assay to determine the IC50. For anti-inflammatory assays, macrophages are pre-treated with NSC 70868 and then stimulated with LPS (1 μg/mL) for 24 hours. Cytokine levels (TNF-α, IL-6, IL-1β) are measured by ELISA. Nitric oxide production is measured using the Griess assay. For assessment of apoptosis, cells are stained with Annexin V-FITC and propidium iodide and analyzed by flow cytometry. For assessment of cell cycle effects, cells are fixed in 70% ethanol, stained with propidium iodide, and analyzed by flow cytometry.
|
| Additional Infomation |
NSC 70868 (CAS# 15347-78-1) is an oxime-active compound (Adipamidoxime) with antimicrobial, anti-inflammatory, and anti-tumor activities. It has a molecular formula of C6H14N4O2 and a molecular weight of 174.20 g/mol. Future research could focus on identifying the molecular targets of NSC 70868, optimizing its biological activities through structural modifications, evaluating its in vivo efficacy in animal models, and developing it as a potential therapeutic for infectious, inflammatory, and neoplastic diseases.
|
| Molecular Formula |
C6H14N4O2
|
|---|---|
| Molecular Weight |
174.20096
|
| Exact Mass |
174.112
|
| CAS # |
15347-78-1
|
| PubChem CID |
9571194
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.37g/cm3
|
| Boiling Point |
454.3ºC at 760mmHg
|
| Flash Point |
228.5ºC
|
| Vapour Pressure |
3.66E-10mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
1.44
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ONC(=N)CCCCC(=N)NO
|
| InChi Key |
KKQNCWWVKWCZID-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H14N4O2/c7-5(9-11)3-1-2-4-6(8)10-12/h11-12H,1-4H2,(H2,7,9)(H2,8,10)
|
| Chemical Name |
1-N',6-N'-dihydroxyhexanediimidamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7405 mL | 28.7026 mL | 57.4053 mL | |
| 5 mM | 1.1481 mL | 5.7405 mL | 11.4811 mL | |
| 10 mM | 0.5741 mL | 2.8703 mL | 5.7405 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
